|
مروری بر عوارض دهانی-صورتی واکسن های کووید-19
|
سیده فرناز طباطبائی    ، ریحانه ایمانی* ، بهاره فرار ، مریم رحیمی خوب |
| گروه آموزشی ترمیمی و زیبایی ، دانشکده دندانپزشکی ، دانشگاه علوم پزشکی آزاد اسلامی تهران ، Reyhaneimani49@gmail.com |
|
|
چکیده: (444 مشاهده) |
سابقه و هدف: هدف از این مطالعه مروری، گردآوری عوارض صورتی-دهانی ناشی از واکسن های کووید19 و شناخت دلایل پیدایش آنهاست.
مواد و روش ها: یک جستجوی الکترونیکی بدون محدودیت تاریخ در پایگاه های داده های MEDLINE از طریق PUBMED و google scholar انجام شد. از بین 50 مطالعه پس از حذف موارد تکراری ، 11 مقاله که معیار های ورود به مطالعه را داشتند مورد بررسی قرار گرفتند و وارد مطالعه شدند.
یافته ها: مطالعه ها نشان داد که تزریق واکسن های کووید 19 ممکن است سبب بروز عوارض جانبی دهانی مانند لیکن پلان ، اریتم مالتی فرم ، سندرم استیون جانسون ، موکوزیت و فلج بل شود و در مطالعه حاضر، عوارض دهانی صورتی از بیشترین شیوع به کمترین آن شامل : فلج بل (6023 مورد) ، خارش پوست و مخاط (39 مورد) ، اریتم مالتی فرم (6 مورد) ، لیکن پلان (6 مورد) ، سندرم استیون جانسون (3 مورد) ، موکوزیت ( 1 مورد) ، انگولار چلایتیس ( 1 مورد ) ، پمفیگوس ولگاریس (1 مورد) و یک مورد با علت نامعلوم میباشد.واکسن فایزر با 3251 مورد عوارض جانبی گزارش شده در این مطالعه ، پرعارضه ترین واکسن می باشد.
نتیجه گیری: با توجه به شیوع بالا کووید 19 و متعاقب آن تزریق واکسنهای کووید 19 به جهت پیشگیری از این بیماری ، تشخیص و درمان عوارض احتمالی به ویژه عوارض دهانی صورتی بعد از تزریق واکسن از اهمیت بسزایی برخوردار است.
|
|
| واژه‌های کلیدی: "، کووید 19"، "، تظاهرات دهانی واکسن کووید 19 "، "، عوارض اروفاسیال واکسن کووید 19"، "، واکسن کووید 19" |
|
|
متن کامل [PDF 626 kb]
(264 دریافت)
|
|
نوع مطالعه: مروری |
موضوع مقاله:
بیماری دهان
|
|
|
|
|
|
|
| فهرست منابع |
1. Sadeghi Dousari A, Taati Moghadam M, Satarzadeh N. COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease. Infect Drug Resist. 2020;(13):2819-28. [ DOI:10.2147/IDR.S259279] [ PMID] [ ] 2. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, Ciccozzi M. COVID-19 Outbreak: An Overview. Chemotherapy. 2019;64(5-6):215-23. [ DOI:10.1159/000507423] [ PMID] [ ] 3. Abebe EC, Dejenie TA, Shiferaw MY, Malik T. The newly emerged COVID-19 disease: a systemic review. Virol J. 2020;17(1):96. [ DOI:10.1186/s12985-020-01363-5] [ PMID] [ ] 4. Nakamichi K, Shen JZ, Lee CS, Lee A, Roberts EA.Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19.Sci Rep.2021;11(1):4802. [ DOI:10.1038/s41598-021-82850-9] [ PMID] [ ] 5. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-78. [ DOI:10.1016/S2468-1253(20)30126-6] [ PMID] 6. Eghbali Zarch R, Hosseinzadeh P. COVID-19 from the perspective of dentists: A case report and brief review of more than 170 cases. Dermatol Ther. 2021;34(1):e14717. [ DOI:10.1111/dth.14717] [ PMID] [ ] 7. Lavery MJ, Bouvier CA, Thompson B. Cutaneous manifestations of COVID-19 in children (and adults): A virus that does not discriminate. Clin Dermatol. 2021 ;39(2):323-8. [ DOI:10.1016/j.clindermatol.2020.10.020] [ PMID] [ ] 8. Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, Spandidos DA, Tsatsakis A. Towards effective COVID 19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3-16. [ DOI:10.3892/ijmm.2020.4596] [ PMID] [ ] 9. Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937. [ DOI:10.1002/jcla.23937] [ PMID] [ ] 10. Michalik S, Siegerist F, Palankar R, Franzke K, Schindler M, Reder A, Seifert U, Cammann C, Wesche J, Steil L, Hentschker C, Gesell-Salazar M, Reisinger E, Beer M, Endlich N, Greinacher A, Völker U. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica. 2022;107(4):947-57. [ DOI:10.3324/haematol.2021.280154] [ PMID] [ ] 11. von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors. Thromb Haemost. 2021;121(11):1395-1399. [ DOI:10.1055/a-1481-3039] [ PMID] 12. Marcucci R, Marietta M. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Intern Emerg Med. 2021;16(5):1113-9. [ DOI:10.1007/s11739-021-02793-x] [ PMID] [ ] 13. Pai M, Grill A, Ivers N, et al. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;1(17):1-7.
https://doi.org/10.47326/ocsat.2021.02.16.1.0 [ DOI:10.47326/ocsat.2021.02.17.1.0] 14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. [ DOI:10.1056/NEJMoa2034577] [ PMID] [ ] 15. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH, Hruza GJ, Blumenthal KG, Fox LP, Freeman EE. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. [ DOI:10.1016/j.jaad.2021.03.092] [ PMID] [ ] 16. Petruzzi M, Galleggiante S, Messina S, Della Vella F. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases. BMC Oral Health. 2022 Mar 24;22(1):90. [ DOI:10.1186/s12903-022-02124-2] [ PMID] [ ] 17. Fadul A, Abdalla EM, Musa M, Al-Mashdali A, Mudathir Osman AE, Abdelmahuod E. Sever erythema multiforme post-COVID-19 moderna vaccine: Case report and literature review. Ann Med Surg (Lond). 2022;83:104461. [ DOI:10.1016/j.amsu.2022.104461] [ PMID] [ ] 18. Zargaran M. Suggested risk factor for oral lichen planus arising after mRNA COVID-19 vaccination. Clin Case Rep. 2022;10(7):e6126. [ DOI:10.1002/ccr3.6126] [ PMID] [ ] 19. Azzi L, Toia M, Stevanello N, Maggi F, Forlani G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. Oral Dis. 2022;28 (2):2583-2585. [ DOI:10.1111/odi.13874] [ PMID] [ ] 20. Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol. 2021;46(8):1615-7. [ DOI:10.1111/ced.14784] [ PMID] [ ] 21. Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64-72. [ DOI:10.1016/S1473-3099(21)00451-5] [ PMID] 22. Di Spirito F, Amato A, Di Palo MP, Contaldo M, D'Ambrosio F, Lo Giudice R, Amato M. Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review. Int J Environ Res Public Health. 2022;19(16):10228. [ DOI:10.3390/ijerph191610228] [ PMID] [ ] 23. Riad A, Põld A, Kateeb E, Attia S. Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports. Front Public Health. 2022;10:952781. [ DOI:10.3389/fpubh.2022.952781] [ PMID] [ ] 24. Padniewski JJ, Jacobson-Dunlop E, Albadri S, Hylwa S. Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Int J Dermatol. 2022;61(8):923-9. [ DOI:10.1111/ijd.16222] [ PMID] [ ] 25. Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T, Kalantari S, Javan A, Goodarzi A, Valizadeh R. Pediatric and adolescent COVID-19 vaccination side effects: A retrospective cohort study of the Iranian teenage group in 2021. J Med Virol. 2022;94(10):4890-900. [ DOI:10.1002/jmv.27962] [ PMID] [ ] 26. Bakir M, Almeshal H, Alturki R, Obaid S, Almazroo A. Toxic Epidermal Necrolysis Post COVID-19 Vaccination - First Reported Case. Cureus. 2021;13(8):e17215. [ DOI:10.7759/cureus.17215] 27. de Las Vecillas L, López J, Morchón E, Rodriguez F, Drake M, Martino M. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine. J Investig Allergol Clin Immunol. 2021;32(1):77-8. [ DOI:10.18176/jiaci.0757] [ PMID] 28. Wunderlich K, Dirschka T. Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2) [Erythema multiforme following COVID-19 vaccination (BNT162b2)]. Hautarzt. 2022;73(1):68-70. [ DOI:10.1007/s00105-021-04911-4] [ PMID] [ ] 29. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889-902. [ DOI:10.1111/j.1365-4632.2011.05348.x] [ PMID] 30. Yousefian M, Khadivi A. Occurrence of erythema multiforme following COVID-19 vaccination: a review. Clin Exp Vaccine Res. 2023;12(2):87-96. [ DOI:10.7774/cevr.2023.12.2.87] [ PMID] [ ] 31. Lavery MJ, Nawimana S, Parslew R, Stewart L. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Clin Exp Dermatol. 2021;46(7):1325-7. [ DOI:10.1111/ced.14714] [ PMID] [ ] 32. Torrelo A, Andina D, Santonja C, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, Hernández-Martín Á, de la Torre-Espi M, Colmenero I. Erythema multiforme-like lesions in children and COVID-19. Pediatr Dermatol. 2020;37(3):442-6. [ DOI:10.1111/pde.14246] [ PMID] [ ] 33. Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, Suarez-Valle A, Saceda-Corralo D, Moreno-Garcia Del Real C, Fernandez-Nieto D. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol. 2020;45(7):892-5. [ DOI:10.1111/ced.14281] [ PMID] [ ] 34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [ DOI:10.1016/S0140-6736(20)30183-5] [ PMID] 35. Herzum A, Burlando M, Molle MF, Micalizzi C, Cozzani E, Parodi A. Lichen planus flare following COVID-19 vaccination: A case report. Clin Case Rep. 2021;9(12):e05092. [ DOI:10.1002/ccr3.5092] [ PMID] [ ] 36. Kulkarni R, Sollecito TP. COVID-19 vaccination: possible short-term exacerbations of oral mucosal diseases. Int J Dermatol. 2021;60(9):e335-6. [ DOI:10.1111/ijd.15779] [ ] 37. Zou H, Daveluy S. Lichen planus after COVID-19 infection and vaccination. Arch Dermatol Res. 2023;315(2):139-46.
https://doi.org/10.1007/s00403-022-02497-y [ DOI:10.1007/s00403-023-02545-1] [ PMID] [ ] 38. Tomo S, Miyahara GI, Simonato LE. Oral mucositis in a SARS-CoV-2-infected patient: Secondary or truly associated condition? Oral Dis. 2022;28 (1):963-7. [ DOI:10.1111/odi.13570] [ PMID] 39. Manfredi M, Ghidini G, Ridolo E, Pizzi S. Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine. Oral Dis. 2022;28 (2):2605-7. [ DOI:10.1111/odi.13912] [ PMID] [ ] 40. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: A case and systematic review. Dermatol Online J. 2018;24(1):13030 [ DOI:10.5070/D3241037941] 41. Kumar R, Das A, Das S. Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines! Indian J Dermatol. 2018;63(2):117-24. 42. Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706. [ DOI:10.1111/bcp.14112] [ PMID] [ ] 43. Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, Deckard NA, Dawson C, Driscoll C, Gillespie MB, Gurgel RK, Halperin J, Khalid AN, Kumar KA, Micco A, Munsell D, Rosenbaum S, Vaughan W. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg. 2013;149(3):S1-27. [ DOI:10.1177/0194599813505967] [ PMID] 44. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450-2. [ DOI:10.1016/S1473-3099(21)00076-1] [ PMID] 45. Principi N, Esposito S. Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes? Front Public Health. 2020;8:361. [ DOI:10.3389/fpubh.2020.00361] [ PMID] [ ] 46. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124(1):27-30. [ DOI:10.7326/0003-4819-124-1_Part_1-199601010-00005] [ PMID] 47. Adour KK, Ruboyianes JM, Von Doersten PG, Byl FM, Trent CS, Quesenberry CP Jr, Hitchcock T. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol. 1996;105(5):371-8. [ DOI:10.1177/000348949610500508] [ PMID] 48. Linder TE, Abdelkafy W, Cavero-Vanek S. The management of peripheral facial nerve palsy: "paresis" versus "paralysis" and sources of ambiguity in study designs. Otol Neurotol. 2010;31(2):319-27. [ DOI:10.1097/MAO.0b013e3181cabd90] [ PMID] 49. Hwang I, Calvit TB, Cash BD, Holtzmuller KC. Bell's palsy: a rare complication of interferon therapy for hepatitis C. Dig Dis Sci. 2004;49(4):619-20. [ DOI:10.1023/B:DDAS.0000026389.56819.0c] [ PMID] 50. Babazadeh A, Miladi R, Barary M, Shirvani M, Ebrahimpour S, Aryanian Z, Mohseni Afshar Z. COVID-19 vaccine-related new-onset lichen planus. Clin Case Rep. 2022;10(2):e05323. [ DOI:10.1002/ccr3.5323] [ PMID] [ ] 51. Borg L, Mercieca L, Mintoff D, et al. Pfizer-BioNTech SARSCoV-2 mRNA vaccine-associated erythema multiforme. J Eur Acad Dermatol Venereol 2022;36:e22-4. [ DOI:10.1111/jdv.17682] 52. Caggiano M, Amato M, Di Spirito F, Galdi M, Sisalli L. mRNA COVID-19 vaccine and oral lichen planus: A case report. Oral Dis. 2022;28 (2):2624-6. [ DOI:10.1111/odi.14184] [ PMID] [ ] 53. Calabria E, Canfora F, Mascolo M, Varricchio S, Mignogna MD, Adamo D. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review. Pathol Res Pract. 2022; 232:153834. [ DOI:10.1016/j.prp.2022.153834] [ PMID] [ ] 54. Hertel M, Schmidt-Westhausen AM, Wendy S, Heiland M, Nahles S, Preissner R, Preissner S. Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients. Vaccines (Basel). 2022;10(3):480. [ DOI:10.3390/vaccines10030480] [ PMID] [ ] 55. Maeda K, Yamashita D, Takenobu T. Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): A case report. J Stomatol Oral Maxillofac Surg. 2022;123(3):283-6. [ DOI:10.1016/j.jormas.2022.01.013] [ PMID] [ ] 56. Saibene AM, Alliata A, Cozzi AT, et al. Erythema multiforme major following SARS-CoV-2 vaccine. Clin Case Rep 2021;9:e04947. [ DOI:10.1002/ccr3.4947] [ PMID] [ ] 57. Sharda P, Mohta A, Ghiya BC, Mehta RD. Development of oral lichen planus after COVID-19 vaccination - a rare case report. J Eur Acad Dermatol Venereol. 2022;36: e82-3. [ DOI:10.1111/jdv.17718] [ PMID] [ ] 58. . Troeltzsch M, Gogl M, Berndt R, Troeltzsch M. Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S). Oral Dis. 2022;28:2595-6. [ DOI:10.1111/odi.14025] [ PMID] [ ] |
|
| ارسال پیام به نویسنده مسئول |
|
|
|
| ارسال نظر درباره این مقاله |
|
|
|
|
طباطبائی سیده فرناز، ایمانی ریحانه، فرار بهاره، رحیمی خوب مریم. مروری بر عوارض دهانی-صورتی واکسن های کووید-19. مجله تحقیق در علوم دندانپزشکی. 1403; 21 (1) :78-91 URL: http://jrds.ir/article-1-1427-fa.html
|
